Molecular blueprint may unlock personalized liver cancer therapy
NCT ID NCT05516628
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resistance, or recurrence. The goal is to pave the way for more personalized treatment decisions in liver cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab plus Bevacizumab
What this could lead to
If successful, this could help doctors choose the most effective treatment for each liver cancer patient, improving outcomes and reducing recurrence.
What could go wrong
This is a small, early-phase study focused on discovery, not treatment. The biomarkers identified may not prove useful in larger, diverse populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changi General Hospital
RECRUITINGSingapore, 529889, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Centre Singapore
RECRUITINGSingapore, 169610, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National University Hospital Singapore
RECRUITINGSingapore, 119074, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sengkang General Hospital
RECRUITINGSingapore, 544886, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Singapore General Hospital
RECRUITINGSingapore, 169856, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tan Tock Seng Hospital
ACTIVE_NOT_RECRUITINGSingapore, 308433, Singapore